Escalation of pharmaceutical opioid use and harm in North America is well-documented, with similar issues emerging in Australia. One response is the development of tamper-resistant formulations of opioids. A potentially tamper-resistant formulation of controlled-release oxycodone was introduced in Australia in April, 2014, rapidly replacing the non-tamper-resistant formulation. Our study is the most systematic and comprehensive examination of the impact of a new opioid formulation to date, assessing the effect of tamper-resistant formulation of controlled-release oxycodone on population-level opioid use and opioid-related harm (ie, overdose, help-seeking, and treatment-seeking); and opioid use, tampering, and preference for the tamper-resistant formulation of controlled-release oxycodone compared with other drugs or formulations among sentinel populations likely to tamper with pharmaceutical opioids.

中文翻译：

---

潜在抗篡改的羟考酮制剂对阿片类药物使用和危害的影响：国家阿片类药物滥用威慑（NOMAD）研究的主要发现。

在北美，阿片类药物类药物的使用和危害不断升级，据记载，澳大利亚也出现了类似的问题。一种反应是开发抗阿片类药物的制剂。2014年4月在澳大利亚推出了可能具有防篡改作用的控释羟考酮制剂，从而迅速取代了非防篡改制剂。我们的研究是迄今为止对新阿片类药物制剂的影响的最系统，最全面的检查，评估了控释羟考酮的防篡改制剂对人群水平的阿片类药物使用和与阿片类药物相关的伤害（即过量，帮助-寻求和寻求治疗）；和阿片类药物的使用，篡改，